| Title |
Smoking is not associated with higher prevalence of JC virus in MS patients
|
|---|---|
| Published in |
European Journal of Clinical Microbiology & Infectious Diseases, February 2018
|
| DOI | 10.1007/s10096-018-3204-z |
| Pubmed ID | |
| Authors |
Michael Auer, Gabriel Bsteh, Harald Hegen, Franziska Di Pauli, Sebastian Wurth, Thomas Berger, Florian Deisenhammer |
| Abstract |
John Cunningham virus (JCV) causes rare, but potentially life-threatening progressive multifocal leukoencephalopathy (PML) in natalizumab-treated multiple sclerosis (MS) patients. Beside JCV index, there is currently no other factor for further risk stratification. Because smoking was reported as potential risk factor for several viral and bacterial infections, we aimed to investigate whether smoking could increase the risk for JCV infection in MS patients. We screened our database of the MS Clinic of the Department of Neurology, Medical University of Innsbruck, Austria, for patients with known smoking status and test result for anti-JCV antibody index as determined by two-step ELISA at Unilabs, Copenhagen, Denmark. In a representative cohort of 200 MS patients with a rate of 36% current smokers plus 6% former smokers, we were not able to detect any association between smoking and JCV status. Furthermore, there was no association between smoking status and anti-JCV antibody index. Smoking does not seem to be a risk factor for JCV infection in MS patients and, therefore, does not represent a suitable marker for PML-risk stratification under treatment with natalizumab. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 20 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 15% |
| Other | 2 | 10% |
| Student > Bachelor | 2 | 10% |
| Unspecified | 1 | 5% |
| Student > Doctoral Student | 1 | 5% |
| Other | 6 | 30% |
| Unknown | 5 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 45% |
| Neuroscience | 4 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Unspecified | 1 | 5% |
| Economics, Econometrics and Finance | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 4 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 February 2018.
All research outputs
#18,587,406
of 23,023,224 outputs
Outputs from European Journal of Clinical Microbiology & Infectious Diseases
#2,186
of 2,792 outputs
Outputs of similar age
#329,481
of 439,455 outputs
Outputs of similar age from European Journal of Clinical Microbiology & Infectious Diseases
#33
of 47 outputs
Altmetric has tracked 23,023,224 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,792 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 439,455 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 47 others from the same source and published within six weeks on either side of this one. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.